These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 17961733)

  • 21. Identification of novel amino acid derived CCK-2R antagonists as potential antiulcer agent: homology modeling, design, synthesis, and pharmacology.
    Gupta AK; Varshney K; Singh N; Mishra V; Saxena M; Palit G; Saxena AK
    J Chem Inf Model; 2013 Jan; 53(1):176-87. PubMed ID: 23240656
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression analysis of a cholecystokinin system in human and rat white adipose tissue.
    Plaza A; Merino B; Sánchez-Pernaute A; Torres-García AJ; Rubio-Herrera MA; Ruiz-Gayo M
    Life Sci; 2018 Aug; 206():98-105. PubMed ID: 29800537
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The efficacy of autocatalytic casapse-3 driven by human telomerase reverse transcriptase promoter on human ovarian carcinoma].
    Song Y; Shen K; Yu JR
    Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(41):2919-24. PubMed ID: 18261307
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Formulation development and manufacturing of a gastrin/CCK-2 receptor targeting peptide as an intermediate drug product for a clinical imaging study.
    Sosabowski JK; Lee M; Dekker BA; Simmons BP; Singh S; Beresford H; Hagan SA; McKenzie AJ; Mather SJ; Watson SA
    Eur J Pharm Sci; 2007 Jun; 31(2):102-11. PubMed ID: 17387005
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimization of 1,3,4-benzotriazepine-based CCK(2) antagonists to obtain potent, orally active inhibitors of gastrin-mediated gastric acid secretion.
    McDonald IM; Black JW; Buck IM; Dunstone DJ; Griffin EP; Harper EA; Hull RA; Kalindjian SB; Lilley EJ; Linney ID; Pether MJ; Roberts SP; Shaxted ME; Spencer J; Steel KI; Sykes DA; Walker MK; Watt GF; Wright L; Wright PT; Xun W
    J Med Chem; 2007 Jun; 50(13):3101-12. PubMed ID: 17536796
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human urine extract CDA-2 induces apoptosis of myelodysplastic syndrome-derived MUTZ-1 cells through the PI3K/Akt signaling pathway in a caspase-3-dependent manner.
    Huang J; Yang M; Liu H; Jin J
    Acta Pharmacol Sin; 2008 Aug; 29(8):951-64. PubMed ID: 18664328
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Responses of human sling and clasp fibers to cholecystokinin (CCK) and gastrin through CCK receptors.
    Liu JF; Gao LP; Wen SW; Lu HL; Zhang J; Sun J; Zhang SW; Wang QZ
    J Gastroenterol Hepatol; 2008 Oct; 23(10):1608-12. PubMed ID: 18444993
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
    McMillin DW; Ooi M; Delmore J; Negri J; Hayden P; Mitsiades N; Jakubikova J; Maira SM; Garcia-Echeverria C; Schlossman R; Munshi NC; Richardson PG; Anderson KC; Mitsiades CS
    Cancer Res; 2009 Jul; 69(14):5835-42. PubMed ID: 19584292
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Construction of autocatalytic caspase-3 driven by amplified human telomerase reverse transcriptase promoter and its enhanced efficacy of inducing apoptosis in human ovarian carcinoma].
    Song Y; Shen K; He CX
    Zhonghua Fu Chan Ke Za Zhi; 2007 Sep; 42(9):617-22. PubMed ID: 17983518
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Z-360, a novel therapeutic agent for pancreatic cancer, prevents up-regulation of ephrin B1 gene expression and phosphorylation of NR2B via suppression of interleukin-1 β production in a cancer-induced pain model in mice.
    Orikawa Y; Kato H; Seto K; Kobayashi N; Yoshinaga K; Hamano H; Hori Y; Meyer T; Takei M
    Mol Pain; 2010 Oct; 6():72. PubMed ID: 20979661
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of cloned tumstatin-related and angiogenesis-inhibitory peptides on proliferation and apoptosis of endothelial cells.
    Zhang GM; Zhang YM; Fu SB; Liu XH; Fu X; Yu Y; Zhang ZY
    Chin Med J (Engl); 2008 Nov; 121(22):2324-30. PubMed ID: 19080341
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-tumor activity of the TRA-8 anti-DR5 antibody in combination with cisplatin in an ex vivo human cervical cancer model.
    Kendrick JE; Straughn JM; Oliver PG; Wang W; Nan L; Grizzle WE; Stockard CR; Alvarez RD; Buchsbaum DJ
    Gynecol Oncol; 2008 Mar; 108(3):591-7. PubMed ID: 18177927
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors.
    Verheul HM; Salumbides B; Van Erp K; Hammers H; Qian DZ; Sanni T; Atadja P; Pili R
    Clin Cancer Res; 2008 Jun; 14(11):3589-97. PubMed ID: 18519793
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High prevalence of fatty acid synthase expression in colorectal cancers in Middle Eastern patients and its potential role as a therapeutic target.
    Uddin S; Hussain AR; Ahmed M; Abubaker J; Al-Sanea N; Abduljabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Bavi P; Al-Kuraya KS
    Am J Gastroenterol; 2009 Jul; 104(7):1790-801. PubMed ID: 19491830
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma.
    Huynh H; Ngo VC; Fargnoli J; Ayers M; Soo KC; Koong HN; Thng CH; Ong HS; Chung A; Chow P; Pollock P; Byron S; Tran E
    Clin Cancer Res; 2008 Oct; 14(19):6146-53. PubMed ID: 18829493
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potential clinical indications for a CCK
    Boyce M; Lloyd KA; Pritchard DM
    Curr Opin Pharmacol; 2016 Dec; 31():68-75. PubMed ID: 27710813
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
    Hu-Lowe DD; Zou HY; Grazzini ML; Hallin ME; Wickman GR; Amundson K; Chen JH; Rewolinski DA; Yamazaki S; Wu EY; McTigue MA; Murray BW; Kania RS; O'Connor P; Shalinsky DR; Bender SL
    Clin Cancer Res; 2008 Nov; 14(22):7272-83. PubMed ID: 19010843
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
    O'Reilly T; Wartmann M; Brueggen J; Allegrini PR; Floersheimer A; Maira M; McSheehy PM
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):1045-54. PubMed ID: 18301895
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy.
    Bao R; Lai CJ; Qu H; Wang D; Yin L; Zifcak B; Atoyan R; Wang J; Samson M; Forrester J; DellaRocca S; Xu GX; Tao X; Zhai HX; Cai X; Qian C
    Clin Cancer Res; 2009 Jun; 15(12):4046-57. PubMed ID: 19509149
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preclinical anticancer activity of the specific endothelin A receptor antagonist ZD4054.
    Growcott JW
    Anticancer Drugs; 2009 Feb; 20(2):83-8. PubMed ID: 19065106
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.